Articles related to Hematology/Oncology

This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo.

The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens.

Although researchers emphasized more research is necessary, a study in Blood Advances demonstrated that tocilizumab may be an effective treatment for patients with COVID-19 and hematologic malignancies.

Can transfusion independence for multiple weeks be possible in patients with myelodysplastic syndromes? Read on to discover promising information you can share with your patients about reducing the severity of their anemia.